Abbott's diagnostic test to detect acute kidney injury receives CE Marking
Abbott has received CE Marking (Conformité Européene) for a new diagnostic test that detects an important protein in urine, neutrophil gelatinase-associated lipocalin (NGAL), an early marker or indicator for patients with, or at risk of, acute kidney injury (AKI).
NGAL is a novel biomarker that can be detected in urine in as little as two hours instead of days. Early detection can aid in the diagnosis of AKI -- a common condition that can quickly progress to kidney failure if left untreated -- and help physicians better manage patient care. Current tests lack the clinical and timely precision that can help physicians intervene quickly and mitigate the effect of any potential injury.
Comments